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Background: Inhaled nitric oxide has been shown to be a potent and
selective pulmonary vasodilator. Reports of increases in left ventricular
end-diastolic pressure and episodes of pulmonary edema during the clinical
use of inhaled nitric oxide in patients with preexisting left ventricular
dysfunction have raised concerns that this agent may have myocardial
depressant effects. We therefore undertook a study of the effects of inhaled
nitric oxide on myocardial contractility in a porcine model of ventricular
failure and pulmonary hypertension. Methods: After inducing heart failure
in 10 pigs by rapid ventricular pacing, hemodynamic measurements and
pressure-volume diagrams (by the conductance method) were obtained in
six animals at baseline and during administration of inhaled nitric oxide at
concentrations of 20 and 40 ppm. Myocardial contractile state was assessed
by the end-systolic pressure-volume relationship and preload-recruitable
stroke work, whereas diastolic function was measured in terms of the
end-diastolic pressure-volume relationship and the pressure decay time
constant T. Results: Baseline hemodynamics reflected heart failure and
pulmonary hypertension, and inhaled nitric oxide induced significant
reductions in mean pulmonary artery pressure and pulmonary vascular
resistance. Although left ventricular end-diastolic pressure increased dur-
ing administration of inhaled nitric oxide, no changes were observed in
measures of systolic or diastolic function. Conclusions: Inhaled nitric oxide
reduced pulmonary vascular resistance but did not alter myocardial
contractility or diastolic function. Increases in left ventricular end-diastolic
pressure during inhaled nitric oxide therapy are therefore not due to
myocardial depression and may be related to increases in volume delivery
to the left side of the heart resulting from reduced pulmonary vascular
resistance. (J Thorac Cardiovasc Surg 1998;115:700-8)
Pulmonary vascular resistance (PVR) is oftenelevated in congestive heart failure. Although
the precise mechanism of this form of secondary
pulmonary hypertension is not known, chronic ele-
vations in left atrial pressure and pulmonary venous
congestion, as well as alterations in sympathetic
tone, are thought to play a role.1 Patients with heart
failure and pulmonary hypertension, whether pri-
mary or secondary, are at increased risk of right
ventricular failure after cardiac transplantation.2
For this reason, demonstration that PVR can be
decreased pharmacologically in such patients (i.e.,
that the pulmonary hypertension is not due to fixed
vascular resistance) is generally a pretransplant re-
quirement.3 In patients receiving left ventricular
(LV) assist devices for advanced heart failure, pul-
monary hypertension often limits the adequacy of
device filling and may require institution of biven-
tricular mechanical support.4
Nitric oxide (NO), initially described as an endo-
thelium-derived relaxation factor, has been impli-
cated in a wide variety of physiologic and pathophys-
iologic processes. Inhaled NO has been shown to
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cause pulmonary vasodilatation in primary pulmo-
nary hypertension,5 in pulmonary hypertension re-
sulting from congenital heart disease,6 and in the
adult respiratory distress syndrome.7 Recently, in-
haled NO has been used to selectively lower PVR in
patients undergoing cardiac operations.8
A clinical report describing the development of
pulmonary edema in patients with heart failure
receiving inhaled NO therapy,9 as well as subse-
quent investigations demonstrating reproducible el-
evations in LV filling pressures,10, 11 have raised
concerns about the use of inhaled NO in patients
with heart failure. Although NO has been shown to
exert negative inotropic effects in some settings,12, 13
it is unclear whether observed elevations in left
atrial pressure are related to direct myocardial
effects of inhaled NO. Although NO is avidly bound
and inactivated by a variety of substrates, including
hemoglobin,14 and is thought not to have effects
beyond arterioles immediately subjacent to alveoli,
evidence suggests that the binding of NO to hemo-
globin may result in the formation of active nitroso-
thiol metabolites.15 We therefore undertook a study
of the effects of inhaled NO on myocardial contrac-
tility in a porcine model of ventricular failure and
pulmonary hypertension, testing our hypothesis that
inhaled NO, when administered at clinically relevant
doses, does not exert negative effects on myocardial
function.
Methods
Animal care. Animals received humane care in compli-
ance with the “Principles of Laboratory Animal Care”
formulated by the Institute of Laboratory Animal Re-
sources and the “Guide for the Care and Use of Labora-
tory Animals” prepared by the Institute of Laboratory
Animal Resources and published by the National Insti-
tutes of Health (NIH Publication No. 86-23, revised 1985).
In addition, this study also conforms with the position of
the American Heart Association on Research Animal
Use.
Induction of heart failure. The protocol16 was carried
out in 10 conditioned female Yorkshire pigs weighing 45
to 50 kg. After induction of anesthesia with ketamine (20
mg/kg) and thiamylal sodium (4.5 mg/kg) and mainte-
nance with isoflurane (1.5 to 2.0%) in 30% oxygen, the
trachea was intubated and the lungs were mechanically
ventilated. A longitudinal subxiphoid incision and partial
inferior pericardiotomy were performed, and a unipolar
pacemaker lead was sutured to the LV apex. Next, a
subcutaneous tunnel and pocket were created, and a
pacemaker (modified Medtronic Model Minix 8340,
Medtronic, Inc., Minneapolis, Minn.) was inserted. After
recovery from anesthesia, the animal was transferred to a
chronic care area. One day after implantation, the pace-
maker was activated at a rate of 230 beats/min with an
external programming device. The animals were moni-
tored daily and given a 3-day regimen of intravenous
cefazolin and a standard diet with free access to water.
Experimental preparation. After 8 days of rapid pac-
ing, the pacemakers were inactivated and animals were
anesthetized with acepromazine maleate (0.5 mg/kg intra-
muscular), fentanyl (100 mg/kg), and atropine (1 to 2 mg
intramuscularly). The lungs were mechanically ventilated,
and ventilatory parameters were adjusted to maintain
normocarbia as determined by frequent blood gas analy-
ses. Normothermia was maintained by the use of two
warming blankets and a heating lamp when necessary.
Anesthesia was maintained with isoflurane (1.5% to
2.0%) in 30% oxygen. Through midline sternotomy and
longitudinal pericardiotomy, the inferior vena cava, pul-
monary artery (PA), and ascending aorta were isolated
with snares. Two 5F micromanometer-tipped catheters
(Millar Instruments, Houston, Tex.) were placed in the
right atrium and PA through purse-string sutures for
continuous pressure monitoring. A 16 mm perivascular
flow probe (Transonics, Ithaca, N.Y.) was placed around
the main PA. This flow probe was connected to an
ultrasonic flowmeter that provided a continuous display of
cardiac output. A 5F Millar micromanometer was placed
in the right external carotid artery and advanced into the
ascending aorta to monitor aortic pressure. A 12-elec-
trode (1.0 cm interelectrode spacing) 6F micromanome-
ter-tipped conductance catheter (Sentron, Federal Way,
Wash.) was inserted through the LV apex and advanced
through the aortic valve into the aortic outflow tract to
measure LV volume and pressure. This catheter was
connected to a signal conditioner (Leycom 5 Cardiody-
namics, The Netherlands) that provides the conductance
signal used for assessing LV volume. This device also
measures blood resistivity, which is necessary for the
estimation of volume. Blood resistivity was measured in
each animal before the start of the experimental protocol.
To ensure proper positioning of the conductance catheter,
echocardiography was used and only segmental volume
signals that corresponded to segments residing in the
ventricular chamber were used for generation of the total
Fig. 1. Representative preload-varying pressure-volume
diagram. P, Pressure; V, volume.
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volume signal. The total conductance signal is not only
affected by the conductivity of blood in the chamber in
which the catheter is situated but also by conductive
structures that surround the chamber. The contribution to
the total conductance signal from these surrounding struc-
tures is termed parallel conductance (Vpc). We deter-
mined Vpc by the hypertonic saline technique rapidly
injecting 5 ml of 5% saline into the PA. Vpc was deter-
mined before each set of measurements, correcting for
changes between NO dose administrations.
NO administration. After endotracheal intubation, an-
imals received a mixture of oxygen and nitrogen to achieve
an inspired fraction of oxygen (FiO2) of 35%. NO gas (800
ppm in N2) (Airco, Riverton, N.J.) was randomly deliv-
ered at concentrations of 20 and 40 ppm by titrating the
amount of N2 downward and the level of NO upward so as
to maintain a constant FiO2 and total gas flow rate of 8
L/min. The inspired concentration of NO was measured
by an NO analyzer (Drager, Chantilly, Va.).
Study protocol. Animals were studied at baseline and
during administration of two doses (20 and 40 ppm) of
inhaled NO. Data collected in each condition consisted of
standard hemodynamic measurements and a series of LV
pressure-volume loops measured before and during infe-
rior vena caval occlusion (IVCO). The IVCO was limited
to 10 seconds to avoid reflex responses and was repeated
if arrhythmias occurred. Mechanical ventilation was sus-
pended during the period of data collection. Measure-
ments were made 5 minutes after reaching a steady-state
concentration of NO at each dose.
Data analysis. All analog signals were digitized at 200
Hz using a 12 bit A-D board (AD Instruments, Milford,
Mass.) and stored on a removable hard drive for subse-
quent analysis using IGOR analysis software (WaveMet-
rics, Inc., Lake Oswego, Ore.). Pressures, flow, and vol-
ume data were subjected to a 5-point binomial smooth
(gaussian filtering). End-diastolic pressure (EDP) was
identified as the point just preceding the upstroke of the
LV pressure wave, and end-diastolic volumes (EDV) were
determined from the lower right-hand corner of the
pressure-volume loop. PVR and systemic vascular resis-
tance (SVR) were calculated using standard formulas. T,
the time constant of active isovolumic relaxation,17 was
calculated using the zero-asymptote method. All steady-
state data represent the average of five consecutive car-
diac cycles.
Three relations derived from the pressure-volume dia-
gram (Fig. 1) were examined during IVCO; at least seven
cardiac cycles free of arrhythmias were used for each
analysis:
1. End-systolic pressure-volume relationship (ESPVR).
The slope, EES, and volume-axis intercept, VO, of the
ESPVR were determined as in previous studies. Briefly,
VO was initially assumed to be 0 ml, and values for
end-systolic pressure (ESP) and volume (ESV) were
determined for each cardiac cycle by identifying the point
at which the value of P(t)/(V(t) – VO) reached a maxi-
mum. Regression analysis of these ESP and ESV points
provided an improved estimate of VO. This updated VO
value was then substituted into the above equation and
new values for ESP and ESV were obtained. Subsequent
iterations were performed until the value of V0 changed
by less than 2 ml.
2. Stroke work-end-diastolic volume relationship (pre-
load-recruitable stroke work, PRSW). Stroke work was
determined for each cardiac cycle by calculating the area
within the respective pressure-volume loop. PRSW was
defined by the relationship between stroke work and EDV
and characterized by the slope (MW) and volume inter-
cept (VW) of this relationship.
3. End-diastolic pressure-volume relationship (EDPVR).
End-diastolic points were identified from each pressure-
volume loop during the IVCO, and the resulting points
were fit to an exponential equation: EDP 5 AeB z EDV,
where A and B are the nonlinear regression coefficients.
In addition, this equation was used to calculate the
predicted EDV at pressure equal to 10 mm Hg (VO),
allowing direct comparison of EDV at a common EDP
between different conditions.18
Statistical analysis. Statistical analyses were per-
formed with InStat for Macintosh (GraphPad Software,
Los Angeles, Calif.). Linear relations (ESPVR, PRSW)
Table I. Hemodynamics at baseline and at increasing concentrations of inhaled NO
Hemodynamic
parameter (units)
Baseline NO 20 ppm NO 40 ppm
Mean SEM Mean SEM Mean SEM
HR (beats/min) 91.2 5.7 87.0 5.4 85.9 6.6
Mean ABP (mm Hg) 87.9 6.2 94.1 5.7 93.4 5.7
CVP (mm Hg) 11.8 2.4 10.4 1.8 10.2 2.1
Mean PAP (mm Hg) 34.7 3.1 29.5* 2.2 29.0* 2.3
CO (L/min) 2.9 0.6 2.7 0.7 2.4 0.5
CO/kg (L/min-kg) 0.060 0.012 0.056 0.013 0.051 0.012
EDV (ml) 122.4 33.1 125.0 34.0 127.6 33.8
EDP (mm Hg) 16.8 3.5 18.1 3.1 19.1‡ 3.4
PVR (Woods units) 6.8 1.7 4.5† 1.0 3.9* 1.2
SVR (Woods units) 32.1 6.6 42.3 11.0 40.4 6.9
EF (%) 25.0 5.4 22.5 4.6 21.2 2.9
NO, Nitric oxide; HR, heart rate; ABP, arterial blood pressure; CVP, central venous pressure; PAP, pulmonary artery pressure; CO, cardiac output; EDV,
end-diastolic volume; EDP, end-diastolic pressure; PVR, pulmonary vascular resistance; SVR, systemic vascular resistance; EF, ejection fraction; SEM,
standard error of the mean.
*p 5 0.02; †p 5 0.04; ‡0.01.
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were described by a slope (m) and a volume-axis intercept
(VO) obtained from linear regression analysis, whereas
exponential equations were expressed in terms of con-
stants A and B. The effect of NO dose on the slope and
VO values of ESPVR and PRSW, the coefficients of the
EDPVR, and hemodynamic parameters was assessed by a
two-way analysis of variance with subsequent comparisons
of individual groups to the baseline group by the Dunnett
post-test. A p value , 0.05 was considered significant.
Results
Hemodynamics. Ten pigs underwent successful
induction of heart failure by use of the described
pacing protocol. During preparation of the exper-
imental setup, one animal (animal 5) died from
ventricular fibrillation on induction of anesthesia
and two others (animals 2 and 10) died from
ventricular fibrillation during median sternotomy.
A fourth animal (animal 3) did not complete the
experimental protocol because of excessive hem-
orrhage and early hemodynamic deterioration.
Baseline measurements in the six remaining ani-
mals reflected biventricular failure and pulmonary
hypertension, with reduced cardiac output and
elevated mean PA pressure, PVR, and LVEDP
(Table I). In addition, all animals exhibited clini-
cal manifestations of heart failure, including as-
cites and pleural effusions, and echocardiograms
performed for purposes of conductance catheter
positioning demonstrated severe chamber dilata-
tion (Fig. 2).
Administration of inhaled NO at concentrations
of 20 and 40 ppm caused no changes in heart rate,
mean systemic arterial pressure, central venous
pressure, SVR, or cardiac output but led to dramatic
reductions in PA pressure and PVR and elevations
in LVEDP (Table I, Figs. 3 and 4).
Contractile state. A representative pressure-vol-
ume diagram is shown in Fig. 1, and representative
ESPVR and PRSW plots under the three study
conditions (baseline and inhaled NO at 20 and 40
ppm) are depicted in Figs. 5 and 6. Notice that the
two relations that describe the ventricular contrac-
tile state appear to be unaffected by the administra-
tion of inhaled NO. The mean values for all animals
are presented in Table II, demonstrating no signif-
icant differences in the slopes or volume intercepts
of either contractile condition under any study con-
dition.
Mean values for parameters that describe the
EDPVR are listed in Table III. No significant
changes were observed in either coefficient A or B.
Consistent with this, the mean volume at a pressure
of 10 mm Hg (VO) was not significantly affected by
either dose of inhaled NO (Fig. 7). In addition, no
evidence of impaired active relaxation was observed
because the pressure decay constant T was unaf-
fected by inhaled NO.
Discussion
The results of this study demonstrate that in a
porcine model of congestive heart failure and pul-
monary hypertension, inhaled NO therapy is not
associated with depression of LV contractile state or
alteration of diastolic properties. Consistent with
clinical reports of NO-induced elevations in pulmo-
nary capillary wedge pressure, we found dose-de-
Fig. 2. Echocardiogram demonstrating four-chamber di-
latation.
Fig. 3. Effects of inhaled nitric oxide (NO) on pulmonary
vascular resistance (PVR).
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pendent rises in LV EDPs. Thus the acute eleva-
tions in LV filling pressures were not due to a direct
myocardial effect of inhaled NO.
Pulmonary hypertension is a common conse-
quence of long-standing congestive heart failure.11
Although mechanisms responsible for this process
are poorly understood,2 chronic elevations in left
atrial pressure, pulmonary venous congestion, intra-
vascular volume expansion, and alterations in sym-
pathetic tone are thought to play a role.1 Interest-
ingly, recent evidence suggests that pulmonary
hypertension may in fact result from impairments in
the release of NO by the pulmonary vascular endo-
thelium19, 20 and that cardiopulmonary bypass–re-
lated endothelial dysfunction may be responsible for
further perioperative elevations in PVR.21 Finally,
the effects of NO on platelet function during cardio-
pulmonary bypass cannot be ignored.22
Whatever the mechanism, secondary elevations in
PVR are initially reactive in nature and are usually
reversible if underlying pathologic processes (e.g.,
congestive heart failure, hypoxia) are corrected
early in their course.23 Persistent elevations in pul-
monary arterial pressures, however, lead to struc-
tural vascular changes, resulting in a fixed, irrevers-
ible form of pulmonary hypertension, the presence
of which is associated with an increased risk of right
heart failure and death after cardiac transplanta-
tion.3 Accordingly, reversibility of pulmonary hyper-
tension with vasodilators such as nitroprusside, and
most recently by inhaled NO,11 is generally consid-
ered to be a requirement in the selection of cardiac
transplant recipients.
Recent reports of left atrial pressure eleva-
tions10, 11 and the development of pulmonary ede-
ma9 during inhaled NO therapy have raised con-
cerns about the safe use of this new agent in patients
with ventricular dysfunction. Given the potential for
inhaled NO to lower PVR in patients with chronic
reactive pulmonary hypertension, to counteract the
pulmonary vasoconstrictive effects of cardiopulmo-
nary bypass, and to evaluate the reversibility of
pulmonary hypertension in cardiac transplant can-
didates, it is clear that patients with heart failure
stand to benefit greatly from the clinical use of this
new agent. For this reason, an understanding of the
mechanism by which inhaled NO causes elevations
in left atrial pressures is clinically important.
Because of the complex interactions between the
ventricles and pulmonary and systemic vascular beds,
identification of the dominant mechanism underlying
an observed hemodynamic effect can be difficult. The-
oretically, left atrial pressure may be influenced, either
independently or in combination, by changes in sys-
tolic function, end-diastolic LV compliance, active
relaxation, or extracardiac parameters, such as total
body volume status, vascular resistance, and venous
tone. Because inhaled NO is inactivated by hemoglo-
bin,24 it should not have direct myocardial effects14 but
might influence ventricular performance indirectly by
its actions on the pulmonary vasculature or through a
stable metabolite or carrier molecule.11, 15
Fig. 4. Effects of inhaled nitric oxide (NO) on pulmonary artery pressure (PAP) pressure, left ventricular
end-diastolic pressure (LVEDP), and transpulmonary gradient (TPG).
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It has been suggested that elevations in left atrial
pressure are a direct consequence of decreases in
LV contractile state induced by inhaled NO.11 In
support of this hypothesis, endogenous NO has been
shown to exert negative inotropic effects under
certain conditions; it was implicated in the myocar-
dial depression induced by endotoxemia and in
response to a variety of cytokines.25, 26 In this study,
although inhaled NO administered at therapeutic
doses caused significant elevations in LVEDP, there
was no effect on ESPVR or PRSW, indicating that
changes in left atrial pressures were not a result of
depressions in contractility.
It has also been hypothesized that elevations in
LVEDP might be related to adverse effects of
inhaled NO on diastolic relaxation, compliance, or
both,11 the latter effect potentially mediated by
NO-induced coronary vasodilatation.27 The effects
on diastolic function of the NO donor sodium
nitroprusside have been studied in isolated heart
preparations and humans,28 revealing changes in
early but not late (isovolumic) relaxation and in-
creases in diastolic distensibility. In our study nei-
ther the isovolumic pressure decay constant (T) nor
the end-diastolic pressure volume relation were
affected by the administration of inhaled NO.
If the LVEDP elevations observed during inhaled
NO therapy are not due to alterations of systolic or
diastolic function, extracardiac mechanisms must be
invoked. In a previous theoretical analysis29 it was
demonstrated in the setting of preexistent LV dys-
function, volume loading, and pulmonary hyperten-
sion that pulmonary vasodilation, by causing shifts
of blood between pulmonary arterial and pulmonary
venous compartments, could by itself account for
elevations of pulmonary venous pressure. This study
concluded that in the presence of significant ventric-
ular dysfunction these pulmonary venous pressure
elevations could increase LVEDP, especially in the
setting of high baseline PVR and volume status. In
this study inhaled NO did not lead to alterations in
systolic or diastolic function. These findings support
the results of the previous theoretical analyses and
indicate that elevations in LV filling pressures ob-
served during inhaled NO therapy are not due to
any measurable direct myocardial effects. Interest-
ingly, in previous experiments in animals with nor-
mal ventricular function, inhaled NO reversed
thromboxane-induced elevations in pulmonary arte-
rial pressures and PVR but did not cause increases
in LVEDP.30
If, as we propose, volume shifts associated with
pulmonary vasodilatation are responsible for in-
creases in LVEDP, one might expect to observe
increases in LVEDV. Although a slight increase was
observed in mean LVEDV after inhaled NO admin-
istration, this difference did not approach statistical
significance. One explanation for this observation,
Fig. 5. Representative end-systolic pressure-volume relationship plot. ESP, End-systolic pressure; ESV,
end-systolic volume; NO, nitric oxide.
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as suggested by Loh and colleagues10 and confirmed
by our analysis, is that because the high baseline
EDV corresponded with the steep portion of the
EDPVR, small increases in LVEDV resulted in
proportionately greater changes in LVEDP, allow-
ing the latter but not the former to reach statistical
significance.
Limitations of the conductance technique for
measuring LV volume are described in detail else-
where31, 32 and predominantly affect the relationship
between conductance and absolute ventricular vol-
ume. To minimize error, we confirmed proper cath-
eter positioning by echocardiography, and gain and
offset values were determined by measurement of
blood resistivity and by the parallel conductance
technique.31, 32 Comparison of the stroke volume
derived from PA flow and by the conductance
technique resulted in considerable variations in gain
(alpha) values among different animals, ranging
from 0.6 to 1.4, but showed no appreciable intraani-
mal variability. Therefore although conductance
volumes were not strictly equivalent to actual vol-
umes and the value of the correction factor alpha
varied between animals, alpha was relatively consis-
tent between individual measurements within the
same animal, allowing valid comparisons to be made
between study conditions because each animal
served as its own control. In addition, general
anesthesia may be considered a confounding factor
because isofluorane is known to induce vasodilata-
tion and may decrease contractility. However, be-
cause each animal acted as its own control, without
alteration of the inhaled concentration of anesthetic
during the course of the experiment, these effects
Fig. 6. Representative preload-recruitable stroke work plot. SW, Stroke work; EDV, end-diastolic volume;
NO, nitric oxide.
Table II. Mean parameters of the ESPVR (Ees , Vo) and the PRSW (Mw , Vo)
Parameter
Baseline NO 20 ppm NO 40 ppm
Mean SEM Mean SEM Mean SEM
EES (mm Hg/ml) 5.7 2.1 5.9 2.1 5.6 2.3
ESPVR Vo (ml) 38.7 13.2 47.3 11.9 46.8 13.6
Mw (mm Hg) 45.6 13.2 43.8 11.8 37.4 8.6
PRSW Vo (ml) 57.1 11.6 60.5 11.1 59.7 15.5
NO, Nitric oxide; EES, slope; ESPVR, end-systolic pressure-volume relationship; Mw, slope; PRSW, preload-recruitable stroke work; SEM, standard error of
the mean.
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are not expected to influence the results of the
study. Finally, the animal model of heart failure
used in this study16 was extremely reproducible,
effecting biventricular dilatation, depression of ejec-
tion fraction, and decreased cardiac output in all
animals tested.
In conclusion, we have reproduced, in a porcine
model of heart failure and pulmonary hypertension,
the constellation of clinically observed hemody-
namic responses to inhaled NO therapy, including
dose-dependent decreases in pulmonary arterial
pressure and PVR and increases in LVEDP. Fur-
thermore, determination of the ESPVR, PRSW,
EDPVR, and T in these animals has demonstrated
no effect of inhaled NO on myocardial contractility
or relaxation. An alternative explanation that has
been proposed on theoretical grounds is that vol-
ume shifts caused by pulmonary vasodilatation are
responsible for clinically observed elevations in
left atrial pressure and may also explain why
patients with preexisting ventricular dysfunction
are at greatest risk for these pressure elevations.
Although clinical validation of our findings in
humans is necessary and is the subject of current
investigations, an understanding of this mecha-
nism may lead to strategies allowing the safe use
of inhaled NO in heart failure, perhaps by adjunc-
tive vasodilator therapy. Considering that in-
creases in LVEDP do not accompany PVR reduc-
tions induced by nonspecific vasodilators (i.e.,
agents that cause both systemic and pulmonary
vasodilation), the importance of increasing sys-
temic vascular capacity in this population during
inhaled NO therapy is underscored.
Fig. 7. Comparison of V10 values derived from the end-diastolic pulmonary vascular resistance. NO, Nitric
oxide.
Table III. Mean values for coefficients of the EDPVR (A, B) and V10
Parameter
Baseline NO 20 ppm NO 40 ppm
Mean SEM Mean SEM Mean SEM
A 0.437 0.216 0.191 0.131 0.118 0.083
B 0.049 0.011 0.061 0.014 0.064 0.015
V10 (ml) 102.2 19.2 105.0 21.0 107.8 22.9
T (msec) 57.7 5.9 60.1 4.5 59.4 5.9
EDPVR, End-diastolic pressure-volume relationship; NO, nitric oxide; T, pressure decoy constant; V10 , volume at P 5 10 mm Hg; SEM, standard error of
the mean.
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